Plain-English translation of NCT06951724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new aspiration catheter — a thin tube designed to remove blood clots from coronary arteries — in patients having emergency treatment for a serious type of heart attack called ST-segment elevation myocardial infarction (STEMI). Researchers want to see if this new catheter works as well as the standard catheter currently used. The study will enroll 144 patients across multiple hospitals.
Blood clots are the main cause of STEMI, and quickly removing them is critical to save heart muscle. This trial exists to find out whether the new catheter design can remove clots just as effectively as the current standard treatment, potentially offering patients a better or equally reliable option.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the aspiration catheter as part of your emergency heart attack treatment — this is not an extra procedure, but rather part of the standard care you would receive anyway. You will be randomly assigned to receive either the new catheter device or the standard catheter device. After the procedure, you will be followed up to monitor your recovery and the effectiveness and safety of the device used.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Sponsor
BrosMed Medical Co., Ltd
Enrollment target
~144 participants
Started
February 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ge Junpo, Ph.D
BrosMed Medical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.